WaveMan
WaveMan · Company
ELVN · Enliven Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

ELVN Enliven Therapeutics (ELVN) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001672619
Quote by TradingView
Form 144 · 5
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
152
13F, latest reported quarter
Conversions, 180 days
15
Codes C/M, not in net · $2.2M priced

What the filings say about ELVN

Insiders, 180 days
-$65.6M net sold
6 sellers · 18% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$13.2M
5 notices

Enliven Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Enliven Therapeutics, Inc. insiders sold a net $65.6M of stock across 319 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Collins Helen Louise
CHIEF MEDICAL OFFICER
SELL
2026-10-21 SECtraded 2026-10-19
5,000
$192.3K
-1.0%
Context
  • 26 earlier Form 4 trades (code P or S) here by this insider (26 sales), the last on Sep 17, 2026.
  • The trade is 20.0% of the 25,000 shares held after it.
  • 2 other insiders sold within 30 days.
  • 152 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF MEDICAL OFFICER Collins Helen Louise sold about $192.3K of ELVN under a 10b5-1 plan on Oct 19, 2026; 2 other insiders sold within 30 days and 152 funds added in the latest 13F quarter.
Hohl Benjamin
CHIEF FINANCIAL OFFICER
SELL
2026-10-21 SECtraded 2026-10-19
6,018
$231.5K
-1.0%
Context
  • 67 earlier Form 4 trades (code P or S) here by this insider (67 sales), the last on Sep 17, 2026.
  • The trade is 15.8% of the 38,000 shares held after it.
  • 2 other insiders sold within 30 days.
  • 152 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF FINANCIAL OFFICER Hohl Benjamin sold about $231.5K of ELVN under a 10b5-1 plan on Oct 19, 2026; 2 other insiders sold within 30 days and 152 funds added in the latest 13F quarter.
Garland J. Scott
Director
SELL
2026-10-05 SECtraded 2026-10-01
13,000
$606.7K
-2.1%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • 2 other insiders sold within 30 days.
  • 152 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Garland J. Scott sold about $606.7K of ELVN on Oct 1, 2026; 2 other insiders sold within 30 days and 152 funds added in the latest 13F quarter.
Collins Helen Louise
CHIEF MEDICAL OFFICER
SELL
2026-09-21 SECtraded 2026-09-17
2,916
$145.9K
-13.9%
Context
  • 23 earlier Form 4 trades (code P or S) here by this insider (23 sales), the last on Aug 17, 2026.
  • The trade is 10.8% of the 27,084 shares held after it.
  • 2 other insiders sold within 30 days.
  • 152 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF MEDICAL OFFICER Collins Helen Louise sold about $145.9K of ELVN under a 10b5-1 plan on Sep 17, 2026; 2 other insiders sold within 30 days and 152 funds added in the latest 13F quarter.
Collins Helen Louise
CHIEF MEDICAL OFFICER
SELL
2026-09-21 SECtraded 2026-09-17
1,844
$93.5K
-13.9%
Context
  • 23 earlier Form 4 trades (code P or S) here by this insider (23 sales), the last on Aug 17, 2026.
  • The trade is 7.3% of the 25,240 shares held after it.
  • 2 other insiders sold within 30 days.
  • 152 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF MEDICAL OFFICER Collins Helen Louise sold about $93.5K of ELVN under a 10b5-1 plan on Sep 17, 2026; 2 other insiders sold within 30 days and 152 funds added in the latest 13F quarter.
319 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 314 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$65.6M over 180 days
-$11.8M over 90 days · -$51.7M of it by a 10%+ holder
below 96% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
152 funds bought in last quarter
more than 82% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
15.4% of the float short (float per yahoo 2026-10-27) · 7.5 days to cover · settled 2026-10-15
more than 80% of Pharma & Biotech
What changed in the last 30 days
Oct 21CHIEF FINANCIAL OFFICER Hohl Benjamin sold $231.5K under a 10b5-1 plan (Oct 19)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 21CHIEF MEDICAL OFFICER Collins Helen Louise sold $192.3K under a 10b5-1 plan (Oct 19)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 19Director Collins Helen Louise filed to sell $559.8K by Oct 19 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 5Director Garland J. Scott sold $606.7K (Oct 1)
Oct 1Director JEFFREY GARLAND filed to sell $606.7K by Oct 1 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.

Watch ELVN

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+101.9%12M
-26%+48%+123%+198%2025-102025-122026-022026-042026-062026-082026-10 2026-06-22 · ORBIMED ADVISORS LLC sold $35.7M2026-06-15 · ORBIMED ADVISORS LLC sold $12.3M2026-08-04 · Derynck Mika K sold $9.6M2026-06-22 · ORBIMED ADVISORS LLC sold $2.1M2026-01-09 · Lyssikatos Joseph P sold $1.5M2026-03-25 · Collins Helen Louise sold $1.4M2026-01-09 · Patel Anish sold $1.3M2026-02-17 · Collins Helen Louise sold $1.2M2026-06-22 · ORBIMED ADVISORS LLC sold $1.1M2026-01-09 · Lyssikatos Joseph P sold $1.0M2026-03-09 · Collins Helen Louise sold $896.7K2026-01-08 · Lyssikatos Joseph P sold $842.3K2026-10-01 · Garland J. Scott sold $606.7K2026-06-15 · ORBIMED ADVISORS LLC sold $409.1K2026-01-20 · Lyssikatos Joseph P sold $390.3K2026-03-10 · Collins Helen Louise sold $305.8K2026-07-06 · Kunkel Lori Anne sold $299.4K2026-03-06 · Hohl Benjamin sold $295.8K2025-11-17 · Kintz Samuel sold $272.8K2026-08-17 · Hohl Benjamin sold $270.2K2025-11-19 · Lyssikatos Joseph P sold $267.8K2026-06-05 · Kunkel Lori Anne sold $266.7K2026-10-19 · Hohl Benjamin sold $231.5K2026-08-17 · Collins Helen Louise sold $227.6K2026-07-06 · Kunkel Lori Anne sold $205.5K2026-01-08 · Heyman Richard A. sold $200.7K2026-10-19 · Collins Helen Louise sold $192.3K2026-09-17 · Hohl Benjamin sold $176.9K2026-01-08 · Lyssikatos Joseph P sold $151.0K2026-06-17 · Hohl Benjamin sold $149.2K2026-09-17 · Collins Helen Louise sold $145.9K2026-02-06 · Lyssikatos Joseph P sold $145.2K2026-01-20 · Lyssikatos Joseph P sold $144.8K2026-07-17 · Hohl Benjamin sold $140.8K2026-03-17 · Collins Helen Louise sold $138.8K2026-05-18 · Collins Helen Louise sold $137.4K2026-07-17 · Hohl Benjamin sold $134.1K2026-04-17 · Collins Helen Louise sold $117.3K2026-07-17 · Collins Helen Louise sold $116.7K2026-04-17 · Collins Helen Louise sold $114.6K2026-06-17 · Collins Helen Louise sold $114.0K2026-09-17 · Hohl Benjamin sold $111.3K2026-10-19 · Collins Helen Louise filed to sell $559.8K2026-10-01 · JEFFREY GARLAND filed to sell $606.7K2026-09-17 · Hohl Benjamin filed to sell $591.2K2026-09-04 · Heyman Richard A. filed to sell $2.3M2026-08-04 · Derynck Mika K filed to sell $9.2M2026-07-17 · Collins Helen Louise filed to sell $762.9K2026-06-22 · The Biotech Growth Trust PLC filed to sell $1.4M2026-06-22 · OrbiMed Private Investments VII, LP filed to sell $36.2M2026-06-22 · OrbiMed Genesis Master Fund, L.P. filed to sell $1.1M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns ELVN: institutional holders (13F)

13F holdings, latest reported quarter
FMR LLC
10,025,017 sh
$508.8M
ORBIMED ADVISORS LLC
6,776,632 sh
$343.9M
Polar Capital Holdings Plc
6,430,636 sh
$326.4M
BlackRock, Inc.
4,359,704 sh
$221.3M
Vestal Point Capital, LP
4,000,000 sh
$203.0M

Congress trades in ELVN

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

ELVN planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Collins Helen Louise
Filed 2026-10-19
$559.8K
JEFFREY GARLAND
Filed 2026-10-01
$606.7K
Hohl Benjamin
Filed 2026-09-17
$591.2K
Heyman Richard A.
Filed 2026-09-04
$2.3M
Derynck Mika K
Filed 2026-08-04
$9.2M

ELVN mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
CapForce IBD Breakout Opportunities ETF
$1.2M position · as of 2026-07-31
7.3%
Lord Abbett Micro-Cap Growth Fund
$5.0M position · as of 2026-07-31
2.3%
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF
$9.0M position · as of 2026-06-30
2.1%
PROFUND VP PHARMACEUTICALS
$233.8K position · as of 2026-06-30
2.0%
Invesco Dorsey Wright Healthcare Momentum ETF
$4.0M position · as of 2026-07-31
1.7%
Direxion Daily Pharmaceutical & Medical Bull 3X Shares
$347.9K position · as of 2026-07-31
1.7%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
4 registered trials, 4 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
4
Phase 1
4 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $65.6M sold by insiders over 180 days, 152 funds added last quarter, $13.2M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

ELVN financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$67.0M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-15.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-15.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-18.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-2.2%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$119.7M-$104.6M-$83.5M-$38.8M
Net income-$103.7M-$89.0M-$71.6M-$37.7M
EPS (diluted)-1.83-1.89-2.01-12.05
Operating cash flow-$70.3M-$73.2M-$61.3M-$32.1M
Cash$98.9M$124.1M$100.1M$75.5M
SEC XBRL, fiscal years, as known on 2026-10-28

ELVN Stock Sonar score 4/7 axes

Find similar shapesCompare

ELVN ranks highest on institutional and government (82nd percentile) and profitability (73rd), and lowest on insider conviction (2nd), among Pharma & Biotech peers.

Profitability
73
Inputs
  • Return on equity-15.3% · 74 pct, sector of 545
  • Return on assets-15.0% · 71 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-18.0% · 74 pct, sector of 576
Insider conviction
2
Inputs
  • Net Form 4 buying (codes P and S), 180d-$64.6M · 3 pct, sector of 429
  • Insider buyers, 180d0 · 0 pct, sector of 438
Institutional and government
82
Inputs
  • Funds adding, latest quarter152 · 82 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
23
Inputs
  • Short interest, % of float+15.4% · 23 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
3 not measured: Financial health, Growth, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

ELVN filings, in plain words

Are Enliven Therapeutics insiders buying or selling ELVN?

In the 180 days to 2026-10-28, Enliven Therapeutics insiders were net sellers, a net $65.6M across purchases and sales reported on Form 4, by 6 sellers.

Are there planned insider sales of ELVN?

Yes. 5 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $13.2M of stock; the latest, by Collins Helen Louise, was filed 2026-10-19.

Read the full summary

In the 180 days to 2026-10-28, Enliven Therapeutics insiders were net sellers of ELVN, a net $65.6M across purchases and sales reported on Form 4 by 6 sellers. Most of that figure, $51.7M, came from a holder of 10% or more rather than an officer or director. 18% of the 44 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 5 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $13.2M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies